Correlation Between Protara Therapeutics and Kiniksa Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Protara Therapeutics and Kiniksa Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protara Therapeutics and Kiniksa Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protara Therapeutics and Kiniksa Pharmaceuticals, you can compare the effects of market volatilities on Protara Therapeutics and Kiniksa Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protara Therapeutics with a short position of Kiniksa Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protara Therapeutics and Kiniksa Pharmaceuticals.
Diversification Opportunities for Protara Therapeutics and Kiniksa Pharmaceuticals
-0.67 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Protara and Kiniksa is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding Protara Therapeutics and Kiniksa Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kiniksa Pharmaceuticals and Protara Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protara Therapeutics are associated (or correlated) with Kiniksa Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kiniksa Pharmaceuticals has no effect on the direction of Protara Therapeutics i.e., Protara Therapeutics and Kiniksa Pharmaceuticals go up and down completely randomly.
Pair Corralation between Protara Therapeutics and Kiniksa Pharmaceuticals
Given the investment horizon of 90 days Protara Therapeutics is expected to generate 4.13 times more return on investment than Kiniksa Pharmaceuticals. However, Protara Therapeutics is 4.13 times more volatile than Kiniksa Pharmaceuticals. It trades about 0.24 of its potential returns per unit of risk. Kiniksa Pharmaceuticals is currently generating about -0.19 per unit of risk. If you would invest 188.00 in Protara Therapeutics on September 23, 2024 and sell it today you would earn a total of 351.00 from holding Protara Therapeutics or generate 186.7% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Protara Therapeutics vs. Kiniksa Pharmaceuticals
Performance |
Timeline |
Protara Therapeutics |
Kiniksa Pharmaceuticals |
Protara Therapeutics and Kiniksa Pharmaceuticals Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Protara Therapeutics and Kiniksa Pharmaceuticals
The main advantage of trading using opposite Protara Therapeutics and Kiniksa Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protara Therapeutics position performs unexpectedly, Kiniksa Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiniksa Pharmaceuticals will offset losses from the drop in Kiniksa Pharmaceuticals' long position.Protara Therapeutics vs. Vaccinex | Protara Therapeutics vs. Monopar Therapeutics | Protara Therapeutics vs. Surrozen | Protara Therapeutics vs. Ikena Oncology |
Kiniksa Pharmaceuticals vs. Nuvalent | Kiniksa Pharmaceuticals vs. Ventyx Biosciences | Kiniksa Pharmaceuticals vs. Arcellx | Kiniksa Pharmaceuticals vs. Cullinan Oncology LLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Complementary Tools
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |